MarketWatch
US · 1 hrs ago
✦ 72◉ Centre
‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug.
72Quality
0Ratings
0Comments
AI Analysis
Quality 72/100
Partisan intensity 45/100
ObjectivePartisan
◉ Centre ⚠ Misleading headline
A new lung cancer drug called ivonescimab showed a 34% reduction in death risk compared to an existing treatment in a clinical trial, but investor enthusiasm for the drug remained muted despite the positive results, suggesting market confidence in the established competitor Keytruda remains strong.
‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!